Funding for this research was provided by:
Received: 27 May 2022
Accepted: 6 July 2022
First Online: 18 July 2022
: Thien Phu Do reports no conflicts of interest.Simon Stefansen reports no conflicts of interest.Mikala Dømgaard reports no conflicts of interest.Timothy J. Steiner reports no conflicts of interest.Messoud Ashina is a consultant, speaker, or scientific advisor for AbbVie, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva and a primary investigator for ongoing AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva trials. Messoud Ashina has no ownership interest and does not own stocks of any pharmaceutical company. Messoud Ashina serves as associate editor of Cephalalgia, associate editor of the Journal of Headache and Pain, and associate editor of Brain.